8/9/2022

speaker
Operator

Good afternoon, and thank you for joining us today for the Neoleukin Therapeutics conference call. At this time, all participants are in a listen-only mode. Following the conclusion of the prepared remarks, we will conduct a question and answer session, and instructions will follow at that time. As a reminder, today's conference is being recorded. I would now like to turn the call over to Julie Rathbun, Communications for Neoleukin Therapeutics. Julie, please go ahead.

speaker
Julie Rathbun
Communications, Neoleukin Therapeutics

Thank you. Good afternoon and welcome to Neoleucin Therapeutics' second quarter 2020-20 conference call. Joining me on the call today from Neoleucin are Jonathan Drachman, CEO, Priti Patel, Chief Medical Officer, and Sean Smith, Vice President, Finance. Today's call is being recorded. It will be available for replay on the investor relations section of the Neoleucin website approximately two hours after the call for at least 30 days. Before we start, I'd like to remind you that today's call will include forward-looking statements based on current expectations. Such statements represent management's judgments, intentions, beliefs, and expectations about future events, strategies, product candidates, and operating plans. All forward-looking statements included in this presentation are made as of today and involve assumptions, risks, and uncertainties. And actual results could differ materially from those anticipated in the forward-looking statements. Neolucan undertakes no obligation to update or revise any forward-looking statements. Please refer to the company's filings with the SEC, which are available from the SEC, or on the Neolucan website for information concerning the risk factors that could affect the company. I'll now like to turn the call over to Jonathan Drachman.

speaker
Jonathan Drachman
Chief Executive Officer

Thank you, Julie, and good afternoon. Neolucan was founded in 2018 based on the vision that de novo protein design will become an important way to design new biologic therapies with customized properties, making them more suited to be therapeutics than native proteins. In the past three and a half years, we have continued to push the boundaries of de novo protein design, learning how to extend pharmacodynamic half-life, fine-tune the affinity of the ligand for its cognate receptor, target the cytokine memetic to specific cells, and how to design increasingly complex molecules. NL201 is the first molecule in this new class of potential therapeutics, and we believe it is the first fully de novo protein to enter clinical testing. Through the ongoing phase one clinical trial, we expect to learn a tremendous amount about the biological effects of de novo proteins in patients and how to continue expanding the capabilities of our technology. In addition to NL201, we have other examples of our de novo protein design capabilities. In 2020, we announced a de novo protein that could prevent SARS-CoV-2 from entering human cells. In 2021, we presented data on an IL-2, IL-15 antagonist that could inhibit IL-2-induced proliferation and protect mice from graft-versus-host disease. And we have more recently announced that we are working on a T regulatory cell agonist with the goal of treating patients with autoimmune or inflammatory diseases. Now we're entering the next phase of de novo protein design technology, which involves adding machine learning and neural networks to computational methods in order to develop new molecules. We have a team of scientists who have been working on this, and we believe it offers advantages for the development of de novo protein therapeutics. Design methods leveraging machine learning can go faster, require less computational power, create designs for more complex proteins, and don't require high resolution crystal structures as a starting point. Over the last six months, we have used this technology to develop prototypes for two additional de novo cytokine memetics. These proteins have established mechanisms of action that we believe could make them promising anti-tumor candidates, and the native proteins have more complex structures than those we have previously designed memetics for. We believe this is the future of de novo protein design, and we're very excited about entering into this next phase with our growing research pipeline. I'd now like to turn the call over to Preeti Patel, our chief medical officer, for an update on ML201. Preeti?

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-